Abstract

The Pittsburgh Cancer Institute (PCI) is a multidisciplinary cancer research center, with programs in prevention and control, early diagnosis and treatment, education and clinical care. The PCI was formed by a consortium of the University of Pittsburgh, Carnegie Mellon University and the six hospitals affiliated with the Medical and Health Care Division of the University of Pittsburgh. The PCI maintains programs in the areas of: clinical investigations, cancer metastases, genetic aspects of carcinogenesis, immunology, viral and cellular oncogenesis, environmental and occupational aspects of carcinogenesis and experimental therapeutics. In addition, programs have been developed in epidemiology and preventive oncology, and biobehavioral oncology. The PCI maintains fifteen shared facilities to assist cancer researchers including: biostatistics office, clinical research support service, immunologic monitoring and diagnostic laboratory, serum and tissue bank, hybridoma facility, transgeneic mouse facility, flow cytometry, protein sequencing, DNA sequencing and DNA synthesis, animal facility, glassware facility, peptide synthesis, molecular genetics marker facility and library resource shared facility. This application requests continued CORE SUPPORT for the Pittsburgh Cancer Institute's programs for years 04-08.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-05
Application #
3101856
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1988-08-01
Project End
1995-07-31
Budget Start
1992-09-03
Budget End
1993-07-31
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost

  Institution

Name
University of Pittsburgh
Department
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213

  Publications

Yockey, Laura J; Jurado, Kellie A; Arora, Nitin et al. (2018) Type I interferons instigate fetal demise after Zika virus infection. Sci Immunol 3:
Chen, Jingci; Nagle, Alison M; Wang, Yu-Fen et al. (2018) Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors. J Biol Chem 293:3700-3709
Qin, Ye; Vasilatos, Shauna N; Chen, Lin et al. (2018) Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene :
Steinman, Justin; Epperly, Michael; Hou, Wen et al. (2018) Improved Total-Body Irradiation Survival by Delivery of Two Radiation Mitigators that Target Distinct Cell Death Pathways. Radiat Res 189:68-83
Evdokimova, Viktoria N; Gandhi, Manoj; Nikitski, Alyaksandr V et al. (2018) Nuclear myosin/actin-motored contact between homologous chromosomes is initiated by ATM kinase and homology-directed repair proteins at double-strand DNA breaks to suppress chromosome rearrangements. Oncotarget 9:13612-13622
Bissel, Stephanie J; Gurnsey, Kate; Jedema, Hank P et al. (2018) Aged Chinese-origin rhesus macaques infected with SIV develop marked viremia in absence of clinical disease, inflammation or cognitive impairment. Retrovirology 15:17
Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi et al. (2018) Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene 37:4599-4610
Diaz-Perez, Julio A; Killeen, Meaghan E; Yang, Yin et al. (2018) Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis. J Invest Dermatol 138:2595-2605
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10
Luu, Thehang; Kim, Kyu-Pyo; Blanchard, Suzette et al. (2018) Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. Breast Cancer Res Treat 167:469-478

Showing the most recent 10 out of 1187 publications